Daraxonrasib’s success in treating pancreatic cancer is a reminder that clinical cancer researchers are heroes

Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science

The oncology community is still riding the high of the success of daraxonrasib—the first drug to show real promise in treating metastatic pancreatic cancer. The drug doubled overall survival for patients in the phase III RASolute-302 trial. At the same time, science continues to become increasingly politicized. The White House Office of Management and Budget released a 412-page proposal May 29 that inserts political appointees into all stages of reviewing and awarding of federal research grants, centralizes OMB control over awarding federal funds, lists “specific principles” that must be applied to review of research programs of all federal entities, including NIH. In this episode of In the Headlines, Paul Goldberg, editor and publisher of The Cancer Letter, and Jacquelyn Cobb, associate editor, talk about how these two stories are inseparable. Political review could put future breakthroughs like daraxonrasib in jeopardy when politicization of science is rooted in distrust. “I was actually thinking of talking to someone who understands Project 2025 to talk about the roots of this kind of dislike for science, which is…I mean, what's not like? Is a treatment for pancreatic cancer a bad thing?” Paul said. Daraxonrasib’s success is thanks to the decades of basic, translational, and clinical research that preceded it, largely funded by federal research dollars. Indeed, the NCI RAS Initiative jumpstarted the field of RAS in 2013.  “To me, the best part of the story, your story, was going back to the link to the NCAB-BSA joint meeting where you could see these guys, with Harold Varmus presiding, deciding what they want to do with the RAS Initiative. By then, you had a pretty good idea that RAS mattered and that it was worth studying. There were already drugs and it was happening.” “It was not a waste of time, but it was also a bet. And it was a smart bet that only NCI could place, and that's why we need to have political appointees—on either party, I don't even care—to look at the entire process, lest those intellectuals get into their idiot heads to cure some other cancer. I mean, my God, that would be awful.” Stories mentioned in this podcast include: * Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival [https://cancerletter.com/clinical/20260605_1/] * The story of daraxonrasib is the ultimate hero’s journey: A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe  [https://cancerletter.com/trials-and-tribulations/20260605_2/] * Political appointees to be inserted into all stages of making research funding awards if OMB rule becomes final  [https://cancerletter.com/the-cancer-letter/20260605_3/] * At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer [https://cancerletter.com/the-cancer-letter/20260605_4/] * Eric Small, ASCO's immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer [https://cancerletter.com/the-cancer-letter/20260605_5/] * Cancer patients could be exempted from Medicaid work requirements if they prove they are “medically frail”  [https://cancerletter.com/cancer-policy/20260605_7a/] * Richard Pazdur joins Friends board [https://cancerletter.com/cancer-policy/20260605_7b/] A transcript of this podcast is available: https://cancerletter.com/podcastc/20260610-omb/

Daraxonrasib’s success in treating pancreatic cancer is a reminder that clinical cancer researchers are heroes

At the American Society of Clinical Oncology annual meeting, the plenary sessions are one of the main events. A handful of clinical research studies are chosen from the thousands that are presented at the conference to represent the biggest achievements from the field in the last year.  This year, results from the phase III RASolute-302 trial were the unequivocal highlight of the plenary hall. With an extended standing ovation, the results showed that patients with metastatic pancreatic cancer who were given daraxonrasib, sponsored by Revolution Medicines, had a median overall survival of 13.2 months compared to a 6.7-month OS for those given chemotherapy. A story about the trial will be in the upcoming issue of The Cancer Letter. But in this week’s In the Headlines, Paul Goldberg, editor and publisher of The Cancer Letter, and Jacquelyn Cobb, associate editor, talk about the buzz that these results are generating. Paul has seen the prognosis of other cancer types—such as  melanoma and multiple myeloma—completely transform after the development of effective drugs.  “I was there when people were saying, ‘Oh, melanoma, forget it.’ But then, suddenly, there was stuff [treatment options]. Melanoma, multiple myeloma—my God, what catastrophe that was. And look at what's happening now. I mean, there's a lot to be said.” Paul said that this is a reminder of the importance of the biomedical research enterprise, and of clinical cancer researchers specifically. In last week’s issue of The Cancer Letter, the cover story was an episode of The Directors, a special segment of The Cancer Letter Podcast, where Paul spoke with two principle investigators of NCI Community Oncology Research Program, or NCORP, sites.  “This is the week where we better take a good look at how well we are treating our clinical researchers. And we better keep looking at it… Seriously, these folks are heroes,” Paul said. “They should be treated well and respected and well funded because guess what? You cannot do ... NCORP brings in about a third of the clinical trials participants. You wouldn't be able to answer the questions we're answering and we better come up with more money for them and continue to come up with more money for them. “You can write about all the rogues in the field all you want, but you know what? There are some really great people who are really moving this field forward and we're all lucky to see this and covering this is a privilege,” Paul said. Stories mentioned in this podcast include: * The Directors: NCORP PIs discuss workforce shortages, expanding workload, and crushing burden of regulatory oversight  [https://cancerletter.com/podcastc/20260529_1/] * When CAM is added to standard therapies, survival rates drop, observational study finds  [https://cancerletter.com/clinical/20260529_2/] * As rural cancer disparities persist, aligning policy with care delivery models can close the gap [https://cancerletter.com/trials-and-tribulations/20260529_3/] * UK Markey’s Denise Fabian: Theranostics lets us pair a diagnostic with a radioactive therapeutic that target the same molecule  [https://cancerletter.com/sponsored-article/20260529_4/] * A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply Warning: This is not a public health recommendation. Do not implement. [https://cancerletter.com/guest-editorial/20240705_3/] A transcript of this podcast is available: https://cancerletter.com/podcastc/20260603-daraxonrasib/

The Directors: NCORP PIs discuss the growing complexity of regulatory oversight in clinical cancer research

Getting NCI clinical trials to the community has never been a simple matter. Has it been getting simpler or more difficult? How does research get done at the NCI Community Research Program sites?  To take the pulse of research in the community, The Directors podcast invited two NCORP principal investigators to ask the questions usually posed to directors of America’s cancer centers: What’s keeping you up at night? NCI Community Oncology Research Program [https://www.cancer.gov/research/infrastructure/clinical-trials/ncorp] is a national NCI-supported network that brings cancer clinical trials and cancer care delivery research studies to people in their communities. In the May episode of The Directors, we speak with Amarinthia Curtis, the medical director of Gibbs Cancer Center and Research Institute and the PI of Upstate Carolina NCORP, and Jeffrey Berenberg, a co-PI of the Hawaii Minority and Underserved NCORP and the Core Clinical Member for Translational and Clinical Research of the University of Hawaii Cancer Center. In the U.S. cancer enterprise, bureaucracy is increasing, compliance burdens are growing, and clinical research is becoming harder to run efficiently. According to Amarinthia and Curtis, it’s frustrating that each agency has its own rules for what counts as a financial conflict of interest, how researchers must disclose it, how often disclosures must be updated, and what dollar amount triggers concern. “I printed out a graph that showed that 60% of the regulations that we have were created in the past 10 years,” Curtis said on The Directors podcast.  “I wasn't aware exactly of that, but my heart, my body can feel that,” Berenberg responded.

As FDA’s wheels almost entirely come off, NCI remains sturdy—a cancer moonshot may even be on the horizon

While every agency under HHS, particularly FDA, has seen historic leadership shakeups and massive cuts to personnel and funding over the course of the second Trump administration—NCI has been spared, even getting a small raise, under the direction of NCI Director Anthony Letai. “For some reason the wheels have not come off NCI, the wheels are very much on and it's kind of moving forward,” said Paul Goldberg, editor and publisher of The Cancer Letter. Is it luck? This has happened in previous administrations. Some agencies have done very well, some have not, Paul said.  But at a recent Senate hearing with the typical contentious moments between Democrats and Republican agency heads, Letai was spared the drama. He wasn’t asked about vapes—a hot button topic of the last few weeks that led to the resignation of FDA Commissioner Marty Makary—and he wasn’t asked about payout rates. Meanwhile, the word “moonshot” was thrown around at a City of Hope-convened symposium on the microbiome. HHS Secretary Kennedy called for a “moonshot” targeted on the role of the microbiome in cancer, which was unexpected. “When people say, ‘Oh, we're going to do a moonshot,’ what they really want to be saying is something like, ‘We are going to project manage this beast, and we're going to emphasize certain kinds of scientific research,'" said Paul. In this episode of In the Headlines, Paul and Jacquelyn Cobb, associate editor of The Cancer Letter, discuss why NCI seems beyond reproach, the microbiome symposium, and the implications of a new cancer “moonshot.” “To me, the microbiome has been this MAHA-adjacent wellness topic that happens to have a really strong scientific foundation,” Jacquelyn said. “So, to me, this moonshot, whatever you want to call it, but this push for microbiome research feels to me like, ‘Oh, there happens to be this … overlap where this is something that the MAHA, RFK people find interesting and find important and it's preventative. It's almost, not holistic, but it's less pharmaceutical, which is, I think, an important point that you talked about, why NCI has to be involved is that there's not necessarily going to be pharmaceutical products that promise profits afterwards, like the typical cancer drug pipeline.” The overlap between the MAHA agenda and cancer research could be impactful. “So, it's just interesting to me where it almost feels like the field is seeing, "Okay, we have this MAHA leader who wants to focus on this type of stuff, what's the highest return subtopic that will actually help cancer patients?" Jacquelyn said. Stories mentioned in this podcast include: * Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer [https://cancerletter.com/the-cancer-letter/20260522_1/] * Marcel van den Brink: Microbiome research is now in “critical phase” where evidence points to therapeutic use [https://cancerletter.com/conversation-with-the-cancer-letter/20260522_2/] * NCI’s Letai gets softball questions from Senate appropriators at an otherwise contentious hearing [https://cancerletter.com/nci/20260522_3/] * USPSTF leaders John Wong and Esa Davis fired by Kennedy, leaving the panel rudderless [https://cancerletter.com/capitol-hill/20260522_4/] * UMGCCC neuro-oncologist navigates the reality of his father’s pancreatic cancer [https://cancerletter.com/guest-editorial/20260522_5/] * FDA’s acting drug chief, acting vaccines chief, and chief of staff ousted in the wake of Makary departure [https://cancerletter.com/cancer-policy/20260522_6a/]

The Cancer History Project debuts first de novo book; meanwhile, FDA snafus continue

In last week’s issue of The Cancer Letter, the cover story featured something special: The first de novo book published by The Cancer History Project. The book, “Backwater to Blockbuster:  St. Jude Children’s Research Hospital,” co-written by Charles J. Sherr and William E. Evans, chronicles the previously untold story of St. Jude Children’s Research Hospital and its rise to becoming a global leader in pediatric cancer research. In this week’s episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, talked about serving as an editor for the book. “I said, ‘Well, if you want, the Cancer History Project, which publishes books, could make this our first de novo book project,’” Paul said that he told Sherr and Evans at the time. “‘And if you want to work with an editor, I have one for you: Me.”’ “And so, in my spare time, I became an editor for this book.” The book is available at no charge on the Cancer History Project website [https://cancerhistoryproject.com/primary-source/backwater-to-blockbuster-st-jude-children-research-hospital/]. “And it's fun because it's kind of a story about the time the Giants walked the earth—giants like Chuck and Bill—by the way. And the cool thing is that there's only one way that the Cancer History Project can publish a book, which is to make it free,” Paul said. In other news, FDA has authorized fruit-flavored vaping products while easing enforcement against illicit products awaiting premarket review, a move critics argue opens the door for major tobacco companies to expand into the flavored vape market. This authorization was the final straw for former FDA Commissioner Marty Makary, who resigned as a result. In this week’s episode, Jacquelyn Cobb, associate editor of The Cancer Letter, and Sara Willa Ernst, reporter, join Paul to talk more about these stories. “It was definitely something new, but it wasn't causing too much alarm among the cancer researchers that I was talking to,” Sara said. “But then a few days later, what we thought was a story turned out to be a different story—which, this is our life in the news and working in journalism. But FDA essentially said, ‘Hey, we're taking a different approach when it comes to enforcement. So, we will be cracking down pretty much on the black market, but one subsection of the black market and not another subject section of the black market.’ Particularly, they will no longer be prioritizing enforcement for black market products that have a pending pre-market application. And so, the experts that we talked to, whether that was a legal expert or other kinds of cancer researchers, they were saying that the way that it might shake out is that the major tobacco companies such as JUUL, that pretty much aren't on the market right now, they kind of have a pathway to be able to put their own products on the shelf without FDA giving them a hassle.” Stories mentioned in this podcast include: * “Backwater to Blockbuster” chronicles the previously untold story of the explosive growth of St. Jude Children’s Research Hospital. In a conversation with Deborah Doroshow, co-authors Chuck Sherr and Bill Evans discuss their collaborative writing process [https://cancerletter.com/podcastc/20260515_1/] * FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applications [https://cancerletter.com/clinical/20260515_2/] * After a year-long reign over tumult at FDA, Makary heads for the exit [https://cancerletter.com/regulatory-news/20260515_3/] A transcript of this podcast is available: https://cancerletter.com/podcastc/20260520-vapes-and-FDA/